Abivax Shares Fall 3.4% at Close After an Exceptional Yearly Run
French biotech company Abivax closed the trading session on Friday, November 28, at 108 euros, down 3.4% from the previous day when it traded at 111.80 euros. This decline follows an impressive upward trend that has boosted the stock since the start of the year. Trading volumes remained limited with only 0.13% of the capital traded, while the CAC 40 gained 0.29% to 8,122.71 points, indicating a decoupling between the stock and the trend of the Paris market.
Contrasting Movements Highlight Abivax's Remarkable Year
The decline recorded this Friday contrasts with Abivax's exceptional trajectory, which shows an annual performance of 1,243%, marking the best progression in the SBF 120 since the beginning of January. Over the week, the stock has shown a modest increase of 0.19%, but the quarterly dynamic remains spectacular with a gain of 56.98%. This correction is part of a technical consolidation movement after the price reached 111.80 euros on Wednesday, November 26. The high volatility of the stock, measured at 18.99 over a month, illustrates the amplitude of daily fluctuations, a typical characteristic of biotechnological values in the clinical phase. With a beta of 0.06, the stock behaves almost independently of the general movements of the Paris market. The absence of significant recent news partly explains this profit-taking after several sessions of gains. The last major catalyst dates back to early November, when Abivax announced the patient-reported outcomes from the phase 3 ABTECT induction trials evaluating Obefazimod, demonstrating a significant improvement in the quality of life for patients with ulcerative colitis. Since this announcement, the market has been gradually digesting these positive clinical data, while anticipating the next regulatory steps. Two executive sales totaling 1,181,754 shares for approximately 111.3 million euros were recorded, while a purchase of 35,456 shares by an executive demonstrates relative management confidence.
Technical Analysis Indicates Potential Consolidation
From a technical analysis perspective, the current price of 108 euros is positioned between the support threshold at 76.10 euros and the resistance at 111.80 euros, which precisely corresponds to the previous day's closing level. The Relative Strength Index (RSI) stands at 77, a level indicating a marked overbought zone and suggesting an increased likelihood of short-term consolidation. This configuration indicates that the stock has undergone an intense accumulation phase and that a technical pullback was technically expected to relieve this excessive bullish tension. The MACD indicator confirms this analysis with a main line at 7.08, significantly above the signal line at 5.44, and a positive histogram of 1.64. This configuration reflects a structurally active bullish trend despite the day's decline. The moving averages reinforce this finding: the price is significantly above the MM50 at 84.46 euros and the MM200 at 38.10 euros, signaling a fundamentally positive trend. However, the stock is trading close to the upper Bollinger band at 113.98 euros, technically materializing a bullish extension close to its statistical limits and justifying the pause observed this Friday.
Shareholder Dynamics Reflect Continued Institutional Interest
In terms of shareholding, Sofinnova Partners crossed the 10% voting rights threshold on November 19, indicating sustained institutional interest despite the high valuation of the stock. The presence of two net short positions representing about 0.51% of the capital reflects some skepticism from certain investors anticipating a possible correction. Abivax's market capitalization now exceeds 8 billion euros, a valuation that incorporates market expectations concerning the results announced in July 2025 from the 8-week induction trials of obefazimod in ulcerative colitis, with maintenance data expected in the second quarter of 2026. Upcoming catalysts will also include the 12-week induction data for Crohn's disease anticipated in the second half of 2026. The exceptional performance of the stock since the beginning of the year remains one of the most remarkable performances in the Paris market, with a more than thirteenfold increase in its valuation, far exceeding the CAC 40's gain of 13.72% over the same period.
